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Abstract Mononuclear phagocytes respond to ischemic stroke
dynamically, undergoing an early anti-inflammatory and pro-
tective phenotype followed by the pro-inflammatory and detri-
mental type. These dual roles of microglia/macrophages sug-
gest the need of subtle adjustment of their polarization state
instead of broad suppression. The most abundant brain-
specific miRNA, miR-124, promotes neuronal differentiation
but can also modulate microglia activation and keeps them
in a quiescent state. We addressed whether the intracerebral
injection of miR-124 in a mouse model of ischemic stroke
before or after the peak phase of the pro-inflammatory po-
larization modifies the pro−/anti- inflammatory balance. In
the sub-acute phase, 48 h after stroke, liposomated miR-124
shifted the predominantly pro-inflammatory polarized
microglia/macrophages toward the anti-inflammatory pheno-
type. The altered immune response improved neurological
deficit at day 6 after stroke. When miR-124 was injected
10 days after stroke, the pro−/anti- inflammatory ratio was
still significantly reduced although to a lower degree and
had no effect on recovery at day 14. This study indicates
that miR-124 administration before the peak of the pro-
inflammatory process of stroke is most effective in support
of increasing the rehabilitation opportunity in the sub-acute
phases of stroke. Our findings highlight the important role
of immune cells after stroke and the therapeutic relevance
of their polarization balance.
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Introduction
Ischemic stroke is a major cause of death and disability world-
wide (Donnan et al. 2008), but presently available therapies
only benefit a small fraction of all patients. In stroke, primary
cell death is directly caused by ischemia, but is followed by
secondary deterioration due to inflammatory response to the
primary event (Dirnagl et al. 1999; Jin et al. 2010). Next to
neutrophils, granulocytes and T-cells infiltrating at day 2–4
after stroke, the early recruitment of central nervous system
(CNS) resident microglia and infiltrating macrophages at
day 1–2 determines strongly the outcome of CNS repair
(Hanisch and Kettenmann 2007). However, these cells
have been shown to play a protective as well as a detri-
mental role. They promote CNS recovery by cleaning up
cell debris and releasing a variety of trophic factors and
cytokines that are important for neurogenesis, axonal regenera-
tion, angiogenesis, and vascular repair (Thored et al. 2009;
Kwon et al. 2013; Hu et al. 2015). On the other hand,
microglia/macrophages can aggravate tissue damage and impair
functional recovery (Ekdahl et al. 2003;Miron et al. 2013). This
dual role has been described as a polarization between two
phenotypes, i.e. the anti-inflammatory, protective state at early
stages of ischemic stroke and the pro-inflammatory, detrimental
state which dominates at later stages (Hu et al. 2012). The two
Electronic supplementary material The online version of this article
(doi:10.1007/s11481-016-9700-y) contains supplementary material,
which is available to authorized users.
* Mathias Hoehn
mathias@sf.mpg.de
1 In-vivo-NMR Laboratory, Max Planck Institute for Metabolism
Research, Gleuelerstrasse 50, D-50931 Köln, Germany
2 Department of Radiology, Leiden University Medical Center,
Leiden, Netherlands
3 Percuros BV, Enschede, Netherlands
J Neuroimmune Pharmacol (2016) 11:733–748
DOI 10.1007/s11481-016-9700-y
activation phenotypes are mainly characterized by increased
protein synthesis of anti-inflammatory mediators such as inter-
leukin-10 (IL-10), IL-4, IL-13, and tumor growth factor β
(TGF-β), or pro-inflammatory mediators such as interferon
γ (IFN-γ), tumor necrosis factor α (TNF-α), and IL-6
(Patel et al. 2013). In addition, pro-inflammatory factors,
including iNOS, CD16, CD32, and CD86 are biomarkers
of microglia/macrophages, which are regarded to be detri-
mental (Jia et al. 2016)(Hirai et al. 2013). In contrast, anti-
inflammatory factors Arg1, CD206, CCL22, Ym1/2 are the
biomarkers of microglia/macrophages, which are considered
to be beneficial (Hu et al. 2012) (Liu et al. 2013). Stroke
induces a systemic immunodepression, which leads to infec-
tions such as pneumonia as a leading cause of death in
patients after stroke. However, preventive antibiotic therapy
and broad immune suppression failed to improve clinical
outcome in stroke patients (Dirnagl et al. 2007; Hu et al.
2012). Therefore, we focused on a novel class of immune
modulators with clinical potential to target specific immune
cell phenotypes and modify their activation state.
A key regulator of microglia quiescence and modulator of
macrophage activation is miR-124 (Ponomarev et al. 2011).
Similar to small interfering ribonucleic acid (siRNA),
microRNAs are small non-protein coding RNAs which bind
to mRNAs and lead to their direct degradation and subsequent
suppression of protein translation (Bartel 2009; Bi et al. 2009).
The most abundant brain-specific microRNA, miR-124, has
been shown to promote neuronal differentiation in neuronal
progenitor cells (Makeyev et al. 2007; Visvanathan et al.
2007). miR-124 is expressed in microglia but not in peripheral
monocytes and macrophages. It affects two main transcription
factors CCAAT/enhancer binding protein alpha (C/EBP-α),
and its downstream target PU.1, resulting in a switch from
an activated state to a non-activated CD45low and major his-
tocompatibility class (MHC) IIlow state (Ponomarev et al.
2011). Peripheral administration of miR-124 in experimental
autoimmune encephalomyelitis caused suppression of the
disease by deactivation of macrophages and reduced acti-
vation of myelin-specific T-cells. Recently, we have been
able to demonstrate that intracerebral administration of
miR-124 after stroke has led to a clear shift of microglia/
macrophages into the anti-inflammatory phenotype, as recog-
nized by the upregulation of the marker Arg-1. This treatment
resulted in a significant correlation of Arg-1 upregulation with
neuronal survival and with functional improvement (Hamzei
Taj et al. 2016).
These earlier results motivated us to investigate in the pres-
ent study how miR-124 affects the polarization ratio of pro-
inflammatory (M1) and anti-inflammatory (M2) phenotypes
in microglia/macrophages after stroke. Although we are aware
of the description of the states with M1 and M2 being a sim-
plified scheme, we decided to stick to this nomenclature as it
best describes our intention of shifting the status from the pro-
inflammatory, detrimental towards the anti-inflammatory, pro-
tective phase. For this purpose, we selected the widely used
CD16/32 as a pro-inflammatory biomarker, which is implicat-
ed in cellular cytotoxicity (Bhatnagar et al. 2014), and the
mannose receptor CD206 as an anti-inflammatory biomarker,
which is involved in tissue recovery and function restoration
(Perego et al. 2011). We show here for the first time that
intracerebral miR-124 administration after stroke results in a
significant increase of microglia/macrophages with M2 phe-
notype, paralleled by a decrease of the M1 phenotype. This
substantial decrease of the M1:M2 ratio correlates strongly
with functional outcome, thus indicating the therapeutic role
for miR-124 in shifting the inflammatory cells into the anti-
inflammatory, protective M2 phenotype.
Material and Methods
Experimental Groups
The aim of this study was to investigate whether the intrace-
rebral injection of miR-124 in a mouse model of ischemic
stroke before or after the peak phase of M1 polarization mod-
ifies the M1/M2 balance. For this purpose, a total of 34 adult
male C57BL6/N mice (11–12 weeks, 21–25 g; Janvier, Saint
Berthevin Cedex, France) were randomly allocated to differ-
ent experimental groups of miR-124 injection and survival
times. Animals were housed under fixed circadian rhythm
with ad libitum access to food and water. All surgical and
scanning procedures were performed under Isoflurane anes-
thesia and core body temperature control. Stroke was induced
in all mice via the middle cerebral artery occlusion (MCAO)
model (cf. below). Successful ischemic stroke lesions were
verified by magnetic resonance imaging (MRI) scans 48 h
after MCAO, before intracranial miR-124 injection, and again
before perfusion fixation at day 6 or day 14, respectively.
In Experiment 1, fifteen mice were subjected to MCAO
and perfused 6 days later, divided into the following three
groups: i) control mice exposed to stroke only (n = 5), ii)
miR-treated mice which received an intracranial injection of
liposomated miR-124 48 h after MCAO (n = 5), and iii) mice
receiving a liposomated random primer injection 48 h after
MCAO (n = 5) as negative control.
In Experiment 2, fourteen mice were subjected to MCAO
and perfused 14 days later, divided into the following three
groups: i) control mice subjected to stroke only (n = 5), ii)
miR-treated mice which received an intracranial injection of
liposomated miR-124 48 h after MCAO (n = 6), and iii) the
negative control group that was injected with a liposomated
random primer 48 h after MCAO (n = 3).
In Experiment 3, stroke was induced in ten mice, and they
were perfused 14 days later, divided into the following two
groups: control mice subjected to stroke only (n = 5), and the
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miR-treated mice with liposomated miR-124 injection at day
10 post MCAO (n = 5).
Middle Cerebral Artery Occlusion
Transient occlusion of the right middle cerebral artery
(MCAO) was induced with the intraluminal filament model,
as described previously (Adamczak et al. 2014). Briefly, mice
were initially anesthetized with 2 % Isoflurane (O2:N2O,
30:70 %) and were subcutaneously injected with 4 mg/kg
Carprofen (Pfizer, Berlin, Germany). The body core tempera-
ture was controlled during surgery via a temperature-regulated
heating pad (medres GmbH, Cologne, Germany). The right
common carotid artery (CCA), external carotid artery (ECA),
and internal carotid artery (ICA) were presented. A silicon
rubber-coated filament with the length of 20 mm and a tip
diameter of 170 μm (7017PK5Re, Doccol Corporation,
Sharon, USA) was advanced into the ICA lumen until it
blocked the origin of MCA. During 30 min occlusion time,
mice were allowed to recover from anesthesia in a controlled
heating box. Afterwards, the animals were re-anesthetized,
the reperfusion was induced by filament withdrawal and
the CCA was ligated. Following surgery, NaCl was sub-
cutaneously injected in all animals twice daily until stabi-
lization of body weight. Only the mice with cortico-striatal
lesion, observed by MRI two days after MCAO, were
selected for the experiments.
Intracranial Injection of Liposomated miR-124
T2-weighted MRI was used to determine the injection coor-
dinates 48 h after MCAO. At the day of injection the miR-124
(2 μg in 50 μl PBS, PM10691 Applied Biosystems, Carlsbad,
CA, USA) or the negative control of miR (2 μg in 50 μl PBS ,
AM17110; Applied Biosystems) was mixed with the trans-
fection agent Lipofectamine 2000 (Invitrogen, Paisley, UK).
Intracranial injection into the right striatum, ipsilateral to the
lesion, was performed as described elsewhere (Aswendt et al.
2012). Briefly, mice were fixed in a stereotactic frame
(Stoelting, Dublin, Ireland), and 2.0 μl of the suspension con-
taining 100 ng of miR or random primer was injected with a
Hamilton syringe (26G needle) at the following coordinates
relative to bregma: AP +0.5; L + 1.4; DV −2.4 with an infu-
sion rate of 500 nl/min. The needle was kept in place for
another 5 min before removal.
Functional Test
To observe the different aspects of neurological functions, a
set of behavioral tests was performed before and every 2 days
after MCAO using the modified neurological deficit scores
(mNDS), a modification of a previous report (Chen et al.
2001). The modified NDS (mNDS) has already been described
recently (Hamzei Taj et al. 2016). In short, it consists of a set of
motor tests (muscle status and abnormal movement), sensory
tests (tactile, and proprioceptive), and reflex tests on a scale of
0–16. One point was given for the failure of a performed test or
for the loss of a tested reflex. Thus, higher scores indicate
higher severity of ischemia.
Magnetic Resonance Imaging
MRI was performed using a 9.4 T Biospec animal MRI sys-
tem with a 20 cm horizontal bore magnet (Bruker BioSpin,
Ettlingen, Germany) equipped with actively shielded gradient
coils (BGA9S, 750 mT/m, Bruker BioSpin), using ParaVision
5 software. Radio frequency (RF) transmission was achieved
with a 112/72 mm od/id mouse resonator (Bruker) while sig-
nal was received with a dedicated quadrature mouse head
surface coil (Bruker BioSpin). Mice were anesthetized with
2 % Isoflurane in a 30/70 oxygen/air mixture and placed in an
animal holder (Bruker) using a tooth bar and ear bars for stable
positioning. Respiration rate was monitored using a pressure
sensitive pad placed underneath the mice. The physiological
status of the animal was monitored with DASYlab software
(National Instruments, Austin, TX, USA). The body core
temperature was monitored with a rectal probe and was
kept constant at 37 ± 1.0 °C using a water blanket con-
nected to a feedback controlled automated temperature
control unit (medres, Cologne).
Tripilot gradient-echo scans were used for definite posi-
tioning of the mouse head in the magnet. For lesion visualiza-
tion, T2-weighted images were acquired with a multi-slice
multi-echo (MSME) spin echo sequence (TR/TE = 5000 ms/
10 ms, 16 echoes, 10 coronal slices, slice thickness 0.5 mm,
FOV 2.5 × 2.5 cm2, matrix 256 × 256, resolution 98 × 98μm2,
bandwidth 75 kHz).
Quantitative T2 maps were calculated from the multi-echo
trains using the IDL software (Exelis Visual Information
Solutions, Boulder, CO, USA), by pixelwise fitting signal
intensities to a mono-exponential decay curve. Average T2
relaxation of the healthy cortex and striatum was determined.
For determination of the lesion volume, all pixels on the ipsi-
lateral hemisphere were counted with T2 values above the
threshold of normal T2 + 2 standard deviations.
Immunohistochemistry
Animals were allowed to survive for 6 or 14 days after MCAO
and were subsequently transcardially perfused under deep
Isoflurane anesthesia with 20 ml cold phosphate buffered sa-
line (PBS), followed by 20 ml 4 % paraformaldehyde (PFA).
Afterwards, brains were post-fixed in 4 % PFA overnight and
then cryo-protected by immersion in 30% sucrose solution for
the next 2 days at 4 °C. Then, brains were frozen in −40 °C
methylbutane (Sigma-Aldrich, Taufkirchen, Germany) and
J Neuroimmune Pharmacol (2016) 11:733–748 735
subsequently stored at −80 °C. The brains were cut into 10μm
coronal slices using a cryostat (Leica Microsystems, Wetzlar,
Germany), directly mounted, and stored at −20 °C.
At the day of immunostaining the cryosections were kept at
room temperature (RT) for 30min, and for stainings of ionized
calcium-binding adapter molecule 1(Iba-1) acetone pre-
treatment at −20 °C for 20 min was performed. To prevent
non-specific binding of antibodies, the sections were pre-
incubated in 5 % normal serum and 0.25 % Triton X-100, in
potassium phosphate buffered saline (KPBS) for 60min at RT.
The treated sections were incubated overnight at 4 °C with
subsequent primary antibodies: rabbit polyclonal anti Iba-1
(1:1000, 019–19,741; Wako Chem, Osaka, Japan), mouse
anti-mannose receptor, MMR/CD206, (1:200, AF2535; R &
D Systems, Minneapolis, MN, USA) and rat anti CD16/32
(1:200, 101,301, Biolegend, San Diego, CA), followed by
Cy5 and Cy3 conjugated secondary antibodies (1:200,
Jackson Immuno Research, West Grove, PA, USA) for 2 h
at RT. For nuclear staining Hoechst 33,342 (1:1000;
Invitrogen, Carlsbad, USA) was added together with second-
ary antibodies. Negatively stained control sections were in-
cluded with equal preparation, excluding primary antibodies.
Three sections per mouse were imaged with a fluorescent
microscope (BZ-9000 Keyence, Osaka, Japan) with 4×, 20×
and 40× magnification objectives. 6 different regions of inter-
est (ROIs) in each brain section were selected with the expo-
sure time kept constant: the border and the core region of the
ischemic hemisphere in the cortex and the striatum, further,
two ROIs in the cortex and striatum of the intact hemisphere.
Quantitative Immunohistochemical Analysis
To observe the polarization of microglia/macrophages, immu-
nofluorescence images were analyzed using NIH ImageJ anal-
ysis software (ImageJ) and TissueQuest 4.0 (TissueGnostics,
Vienna, Austria), a specific image cytometry analysis soft-
ware. Cells were identified on the tissue section based on the
nuclei staining (nuclei size, staining intensity and discrimina-
tion by area was optimizedmanually) followed by the analysis
of specific staining. To achieve optimal cell detection the
background threshold was defined and due to the coverage
of Iba-1 cell ramification with total nuclei intensity, the cut-
offs were defined for each ROI to discriminate false signals.
Scattergrams were created to visualize the corresponding pos-
itive cells in the source ROI through the real-time back gating
component. Mean intensity and the relative number of co-
expressed Iba-1 and CD206 or CD16/32 were obtained, and
mean values were estimated from analyses of at least three
brain sections per mouse. To observe M1 and M2 representa-
tive markers in double staining with Iba-1, the above-defined
6 different ROIs provided the following number of cells/mm3:
i) total cell density according to the nuclei staining, ii) Iba-1+
microglial/macrophage cell density, iii) CD206+/Iba-1+ cell
density, iv) CD16/32+/Iba-1+ cell density. Then, a mean was
calculated for each region for each animal.
Statistics
Data were analyzed by SPSS version 22 (IBM SPSS statistics,
Ehningen, Germany). The Normality test and homogeneity of
variances were evaluated for all data. For behavioral scores
(mNDS) the nonparametric analysis approach, Kruskal-Wallis
H, was performed. IHC data from early time point of
liposomated miR-124 injection at day 2 were tested for sig-
nificant changes between the 3 groups using one-way analysis
of variance (ANOVA) with Bonferroni corrected posthoc
comparisons. Using an independent one-tailed Student’s t-test,
we tested the data of late liposomated miR-124 injection to
observe the significant changes between the stroke-only group
and the group treated with miR-124 at day 10.
The IHC numbers are represented by box-and-whisker
plots (Figs. 3, 4 and 6) wherein each box shows the central
50 % of the data points, the interquartile range (IQR), a hor-
izontal line in each box indicates the median, and the vertical
bars speak for the spread of 1.5 × IQR. Dots display outliers,
which were included in calculations of significance. The box-
and-whisker plots were generated by using SPSS version 22.
Bivariate correlation analysis between M1/M2 expression
by Iba-1+ cells and mNDS were measured with Spearman’s
correlation coefficient. Regression was done with M1/M2
expression by Iba-1+ cells as the independent variable and
mNDS as the dependent variable. A p-value ≤0.05 was
regarded statistically significant.
Results
Characterization of Ischemic Lesion after Ischemia
Two characteristic lesion types were generated 1) lesions re-
stricted to the striatum and 2) lesions involving both striatum
and cortex. We excluded the striatal-only ischemic mice from
further experiments and used only a homogeneous group of
cortico-striatal lesions. Quantitative MRI T2 maps of the in-
cluded animals were acquired before stroke induction, and at
day 2 and day 6, respectively at day 2 and day 14 after
MCAO, for experimental protocol 1 and 2. Thus the acute
and chronic ischemic lesion location, the size and the devel-
opment were detected (Fig. 1). One week before MCAO, T2
maps showed no signs of lesion and the healthy subjects
presented equal T2 values of both hemisphere. At day 2
after MCAO, areas with markedly increased T2 values
showed the development of the lesion extent over time. A
gradual decrease in lesion volume was visible on the T2 maps
at day 6 or day 14 (Fig. 1), showing that the vasogenic edema
continuously resolved. A quantitative analysis of the lesion
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volume based on the elevated T2 relaxation time in the ische-
mic territory showed no significant difference between groups
for all three experimental protocols (Suppl. Fig. 1).
Morphology of Microglial/Macrophage after Stroke
First we examined the morphology of ionized calcium-
binding adapter molecule 1(Iba-1) positive immune cells in
the stroke core, the border and the surrounding healthy tissue.
Iba-1 detects CNS resident microglia and infiltrating
monocyte-derived macrophages.
Iba-1 positive cells were visible in both intact and ischemic
hemisphere, although with different morphology and distribu-
tion. They were densely gathered in the ischemic hemisphere
around and inside the lesion (Fig. 2a). Microglia/macrophages
were categorized into ramified, intermediate, amoeboid or
Fig. 1 Characterization of
ischemic lesion after ischemia.
Representative T2map of three
experimental groups subjected to
MCAO and perfused at day 6 or
day 14, respectively. T2 maps are
shown as coronal brain section.
T2 map of intact subjects, 1 week
before MCAO, shows equal
intensity of both hemispheres.
48 h after MCAO the
cortico-striatal lesions are visible
in the right hemisphere in
T2-weighted images. A gradual
shrinkage of infarct volume was
visible at days 6 and 14 compared
to day 2, showing the continuous
reduction in vasogenic edema
after stroke
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round phenotypes. The ramified type with long thin branching
processes and a small cell body was mostly observed in the
contralateral hemisphere and in the healthy parts of the ipsi-
lateral ischemic hemisphere. In the peri-infarct area, the ma-
jority of Iba-1+ cells acquired the intermediate morphology
with short or long swollen processes and amorphous larger
cell body. In contrast, amoeboid and round shaped Iba-1+ cells
were exclusively found in the ischemic core (Fig. 2b).
We noted a pronouncedly higher Iba-1+ cell density in the
striatum at day 6 when compared with the results of day 14
post stroke (Fig. 2c), emphasizing the increased early stage
proliferation of Iba-1+ cells after stroke.
miR-124 Effects on Microglia/Macrophages after Stroke
We further evaluated the influence of liposomated miR-124
(injection at day 2 after MCAO) on the expression of Iba-1 at
different time points after MCAO (Immunohistochemical
analysis at day 6 Fig. 3a and day 14 Fig. 3b). Intracerebral
injection of miR-124 at day 2 after stroke led to a significant
increase in the number of Iba-1 cells. No significant difference
in the number of Iba-1 positive cells was found between
the MCAO-only and negative control group. At day 6
post MCAO, all ipsilateral interquartile ranges of Iba-1+
cell numbers were higher in the miR-124 treated group
Fig. 2 Different morphology and
kinetics of microglial/
macrophage after stroke. The
photomicrographs show the
localization of Iba-1 positive cells
intensely at the ipsilateral
ischemic hemisphere at day 6
after stroke in 4× magnification
(a), and the different morphology
of microglial/macrophage cells
classified into ramified,
intermediate, amoeboid or round
phenotype in 20× magnification
(b). Representative graph shows
the number of Iba-1 positive cells
in the core and border zone of
cortex and striatum at day 6 in
comparison to day 14 after stroke
(c). A significant increase in Iba-1
cell number was detected at day 6
after the onset of stroke. n = 5
mice for each time point. Median
and minimum/maximum values
are shown; *P< 0.05 at
independent one-tailed Student’s
t-test. Scale bar 50 μm
738 J Neuroimmune Pharmacol (2016) 11:733–748
compared to both, the MCAO-only and the negative control
group (Fig. 3a).
To observe the long term effects of the early injection of
miR-124 on microglia/macrophage cells after stroke, we eval-
uated the Iba-1 cell number of the second experimental time
point, where miR-124 or the random primer was injected
2 days after MCAO and animals were perfused at day 14 for
immunohistochemical analysis. The density of Iba-1+ cells at
day 14 markedly decreased in all 3 groups in all ipsilateral
regions of interest, in comparison to the situation at day 6 post
stroke (Fig. 3a, b). The Iba-1+ cell number in the cortical ROIs
are at closely the same level in the three experimental groups
(Fig. 3b).
Modulation of Microglia/Macrophage Polarization
by Early miR-124 Application
Microglia/macrophages exhibit dynamic polarization over
time, transforming from alternatively activated M2 phenotype
to classical, activated M1 phenotype. We evaluated the char-
acteristic polarization of microglia/macrophages after MCAO,
using the representative M1-associated (CD16/32) or M2-
associated (CD206) markers for double immunofluorescent
staining together with Iba-1 in the ischemic territory (Fig. 4
for CD206; Fig. 5 for CD16/32). In both, theMCAO-only and
negative control group, the expression ofM1marker CD16/32
in Iba-1+ cells was high at day 6 after stroke and remained
elevated until day 14 after ischemia (Fig. 5d, e). In contrast,
the immunofluorescence for the M2 marker CD206 was
slightly decreasing over time from day 6 until day 14 in both
groups (Fig. 4d, e).
Intracerebral administration of 100 ng miR-124 at day 2
after MCAO resulted in a strongly significant increase of Iba-
1+ cells expressing CD206 at day 6 post stroke. Interestingly,
at this time point, theM2marker expression tends to be higher
in the border areas than in the core of the ischemic lesion in the
miR-124 treated group, emphasizing the anti-inflammatory
role of miR-124 in the penumbra (Fig. 4d). However, in com-
parison of the three experimental groups, no significant long-
term effects of miR-124 onM2marker expression were noted,
although the miR treated group showed larger interquartile
range in the cortex areas of the ischemic hemisphere indicating
a trend towards a higher amount of CD206 expression by Iba-1+
cells at day 14 after MCAO (Fig. 5e, Suppl. Fig. 2).
The immunofluorescence staining for M1marker CD16/32
on Iba-1+ cells decreased significantly in the miR-124 treated
group compared to both control groups at day 6 after MCAO.
Almost all the relevant 50th percentile and the middle 50 % of
the ipsilateral ROIs of this group were in lower level, indicat-
ing a noticeably lesser pro-inflammatory environment in this
miR-124 treated group (Fig. 5d). With miR-124 treatment the
M1 response increased strongly from 6 days to 14 days after
MCAO, indicating the decreasing effect of miR-124 twelve
days after injection (Fig. 5e).
Consequently, the early intracranial injection of miR-124
had a significant effect on the ratio of anti-inflammatory to
Fig. 3 miR-124 effects microglial/macrophage kinetic after stroke.
Densities of Iba-1 positive cells in the border and core zone of cortex
and striatum area inmiR-124 treated group comparing to the onlyMCAO
and negative control group at day 6 (a) and day 14 after stroke (b). A
significant increase in Iba-1 cell number in miR-124 treated mice was
detected at day 6 after stroke. No significant difference in number of Iba-1
positive cells was found between the groups at day 14 after stroke. n = 5–
6 mice in each group and for each time point. Median and minimum/
maximum values are shown; *P< 0.05, **P < 0.01 at one-way ANOVA
(with Bonferroni’s post hoc test)
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Fig. 4 Effect of miR-124 on M2 phase of microglia/macrophages.
Photomicrographs show examples of double-staining immunofluorescence
of CD206 and Iba1 on brain sections of ischemic core and border zones
acquired from three experimental groups at 6 days after stroke. Illustrative
4×, 20× close-up magnification visualize the changes in CD206 expression
by Iba-1 positive cells (a-c). Scale bar: 50 μm. Time course for the CD206
expression by Iba-1+ cells in the ipsilateral and contralateral ROIs of cortex
and striatum in miR-124 treated group comparing to the only MCAO and
negative control group at day 6 (d) and day 14 (e). Quantification results
confirm that intracranial injection of miR-124 at day 2 after MCAO results
in a vigorous increase of Iba-1+ cells expressing CD206 monitored at day 6
post stroke (d). Representative graph shows no differences of CD206
expression by Iba-1+ cells at day 14 after stroke between groups (e).
n = 5–6 mice in each group and for each time point. *P < 0.05,
**P<0.01 at one-way ANOVA (with Bonferroni’s post hoc test). Scale
bar 50 μm
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pro-inflammatory phenotype in the first week after MCAO
(Fig. 7).
Effects of Delayed miR-124 Injection on M1/M2
Phenotype of Microglia/Macrophages
We investigated whether miR-124 application can also shift
between the M1 and M2 phenotype at a later time after stroke
when the pro-inflammatory M1 phenotype has already be-
come dominant. To survey its effects at this later stage of
stroke evolution, miR-124 was injected 10 days after
MCAO, and the polarization of microglia/macrophages was
analyzed 14 days after MCAO. No significant difference was
observed in the M2 expressing Iba-1+ cell number between
the miR-124 treated and the stroke-only group (Fig. 6e). The
median of both groups did not differ in the cortical regions,
however the 50th percentile of the ipsilateral striatal regions of
miR-124 treated group were higher, pointing towards slightly
increased M2 marker expression by Iba-1+ cells adjacent to
the injection channel (Fig. 6e). Interestingly, a pronouncedly
lower level of M1 marker expression by Iba-1+ cells was
clearly visible in the miR-124 treated group, particularly in
the border and core regions of the striatal lesion (Fig. 6f).
The coherent interquartile range and the 50th percentile of
all ipsilateral ROIs in the miR-124 treated group are at a re-
markably lower level confirming the reduced M1 to M2 ratio.
Analyzing the M1:M2 ratio directly demonstrates a signifi-
cantly lower ratio under miR-124 treatment in all experiments.
While the M1:M2 ratio of the miR-124 treated group is in-
creasing with time after application, indicating a slowly weak-
ened treatment effect, it remains still significantly lower even
when miR-124 is applied only after ten days (Fig. 7).
Taken together, we have demonstrated that the delayed
miR-124 administration after stroke still can modify the mi-
croglia and macrophage polarization while early application
of miR-124 administration after stroke is needed to achieve
maximal increase of protective M2 in parallel with pro-
inflammatory M1 decrease.
Neurological Deficit Scores
We assessed whether intracerebral application of liposomated
miR-124 improves functional recovery after stroke in mice,
using the modified neurological deficit scores (mNDS). In all
groups, 30 min MCAO increased the neurological deficit
scores (up to 8 mNDS) compared to the days before stroke
(0 mNDS) indicating impaired motor and sensory functions.
Injection of miR-124 at two days after MCAO significantly
reduced mNDS scores at 4 and 6 days (P 0.05; 6 and 4mNDS,
respectively) compared with the stroke-only and negative con-
trol group (8 mNDS). Slight differences were observed be-
tween the stroke-only and negative control group, however
the differences were not significant (Fig. 8a, b). The mice
treated with liposomated miR-124 at day 10 showed no
treatment effect onmNDS scores (Fig. 8c). Our findings clear-
ly indicate that the neurological deficits caused by 30 min
MCAO in mice can be improved by early miR-124 injection.
Correlation of M1/M2 and NDS
Liposomated miR-124 treatment resulted in improved func-
tional recovery, which was paralleled by the observation of
decreased CD16/32 (M1) and increased CD206 (M2) expres-
sion of microglia/macrophages. We subsequently performed
Spearman correlation analysis of M1 and M2 expression with
the neurological deficit scores (Fig. 8d, e). Correlation anal-
ysis showed a positive linear relation between CD16/32
expression by Iba-1 positive cells and an increased neuro-
logical deficit score at day 6 after stroke with a linear
equation NDS = 2.777 + 0.011 (CD16/32) (r2 = 0.530 ,
p = 0.017), (Fig. 8d). A negative linear correlation was
found between CD206 expression by Iba-1 positive cells
and an increased neurological deficit score at day 6 after
stroke with an equation NDS = 8.455–0.009 (CD206)
(r2 = 0.425, p = 0.041), (Fig. 8e). However, there was no
correlation at day 14 post stroke.
Discussion
The main finding of the present study is that local miR-124
injection after ischemic stroke improves the neurological
score at day 4 and 6. The improved motor and sensory func-
tions are directly correlated to the number of M2-like and
inversely correlated to the number of M1-like microglia/mac-
rophages. Taken together, our data present miR-124 as a
promising molecule to modulate the microglia/macrophage
activation state, and subsequently to improve the stroke
recovery.
Early Administration of miR-124, 2 days after Ischemic
Stroke
In an effort to control the phenotypic shift of microglia/
macrophages as a therapeutic strategy for brain disorders, we
present a previously unreported role of the brain specific
microRNA-124 in modulating the polarization of microglia
and infiltrating macrophages in the sub-acute phase of ische-
mic stroke. We show here for the first time that miR-124
administration at 48 h after ischemia, before the pro-
inflammatory peak of stroke (Hu et al. 2012), changes the
M1/M2 balance toward a more anti-inflammatory phenotype
and improves functional recovery at the first week after mid-
dle cerebral artery occlusion. The early miR-124 treatment at
day 2 after ischemia gave rise to a strong increase of Iba-1+
cells expressing the M2 marker CD206 and a parallel
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pronounced decrease of the M1 marker CD16/32, highlight-
ing the protective role of miR-124. In support of our experi-
mental data, we observed a significant negative correlation
between high M2 expression levels and neurological deficit
scores in miR-124 administrated ischemic mice at day 6,
paralleled by a significant positive correlation of the M1 level
with neurological deficit scores.
Microglia/macrophages react dynamically to ischemic injury
over time: in the acute phase the vast majority of recruited
microglia and macrophages in CNS diseases are M2-dominant,
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providing protective functions, but by about 1 week after injury
the M1 phenotype becomes predominant (Kigerl et al. 2009;
Perego et al. 2011;Wang et al. 2013). ThemRNA expression of
M2 phenotype markers (CD206, Arg-1, Ym1/2, IL-10, and
TGF-β) peaks between day 3 to day 5 post injury, while the
M1 phenotype relevant genes (iNOS, CD16, CD32) are contin-
uously increasing over time from day 3 on. They remain ele-
vated still at day 14 after stroke (Hu et al. 2012; Pan et al. 2015).
This is in agreement with the expression peak of IRF-4 at day 3,
a key transcription factor of M2 polarization phenotype, where-
as expression of IRF-8, a transcription factor of M1 polarization
phenotype, increases within 72 h after ischemia (Guo et al.
2014; Xiang et al. 2014). The M2 phenotype promotes the
CNS repair and regeneration, emphasizing that well timed
counteraction of M2 on M1 should be a promising cell-based
regenerative strategy in stroke.
We have shown that miR-124 enhances and prolongs
the M2 phase while reducing the M1 process. Moreover,
our results of improved functional outcome are in line
with our earlier results, showing an upregulation of the
M2-phenotype marker Arg-1 upon early administration of
miR-124 after stroke (Hamzei Taj et al. 2016). In those
studies, we could also find a negative correlation of Arg-1
expression with the neurological deficit score, paralleled
by a positive correlation of Arg-1 cell expression with
neuronal survival (Hamzei Taj et al. 2016). Further support
for our finding of miR-124 induced improved functional out-
come comes from Ponomarev (Ponomarev et al. 2011), who
reported that bone marrow-derived macrophages, transfected
with miR-124, downregulate the expression of theM1markers
TNF-α and inducible nitric oxide synthase (iNOS), and simul-
taneously upregulate the expression of the M2 markers
TGF-β1, Arg-1 and FIZZ1 (Found in inflammatory zone 1)
by inhibition of the C/EBP-α transcription factor responsible
for downregulation of PU.1. A similar M1/M2 ratio modula-
tion of microglia and macrophages in the spinal cord was
achieved via intrathecal injection of liposomated miR-124 in
an IL-1β induced hyperalgesia model, leading to reduced
inflammatory reactions and neuropathic pain (Willemen et al.
2012).When transfecting primarymicroglia isolated from neo-
natal rats with miR-124/chitosan complex particles, expression
of TNF-α and inducible NO synthetase (iNOS), two major
substances of M1 phenotype, was reduced. Microinjection of
miR-124/chitosan particles was also shown to reduce the in-
flammation in a rat model of spinal cord injury (Louw et al.
2015). On the other hand, knockdown of miR-124 via a miR-
124 antisense oligonucleotide inhibitor was reported to activate
the microglia and macrophages, presenting upregulated MHC
class II and CD45 in addition to inhibiting the development of
ramified morphology of the cells (Ponomarev et al. 2011).
It is worth noting that the induced modulation of immune
response after stroke was mostly due to miR-124 injection in
the present study and not because of intracranial injection
procedure. Interestingly, however, the early injection of nega-
tive control of miR at day 2 after ischemia only gave rise to a
smaller M1 marker expression by Iba-1+ cells in comparison
to the stroke only group. In support of our observation, Le
Blon and colleagues observed fewer MHCII+ expressions
by Iba-1+ cells, as M1 associated marker, in sham im-
planted group in a mouse model of mesenchymal stem
cell implantation (Le Blon et al. 2014).
The M1/M2 modulating effect of the liposomated miR-124
was decreasing from day 6 to day 14 in our experiment.
Although the number of CD206+/Iba-1+ cells and CD16/32+/
Iba-1+ cells of the miR-124 treated group are no longer statis-
tically significantly different from the corresponding cell num-
ber of the control groups, a clear difference is still noted
resulting in the significantly lower M1:M2 ratio of the treated
group (cf Fig. 7). We suggest that the time dependent decrease
of the miR-124 immunomodulatory effect is explained by the
short half-life of microRNAs of a few days only (Krol et al.
2010; Gantier et al. 2011). With a different route of miR-124
delivery the long term effect may be extended or even en-
hanced. Thus, Doeppner et al. presented sustained neuropro-
tection and ameliorated motor coordination and memory
acquisition up to 56 days upon stroke onset by a viral
vector-mediated miR-124 delivery (Doeppner et al. 2013).
In correspondence to that, our findings of a decreasing immu-
nomodulatory effect after a single injection of liposomated
miR-124 together with the still persistent effect upon delayed
injection indicates that future protocols with repetitive injec-
tions of liposomated miR-124 may provide a sustained low
M1:M2 ratio.
Delayed Administration of miR-124, 10 days
after Ischemic Stroke
We found that intracerebral injection of liposomated miR-124
at the chronic stage after stroke onset, administered at day 10,
still has substantial influence on the microglia/macrophages.
However, while at early miR-124 application M2 was
Fig. 5 Effect of miR-124 on M1 phase of microglia/macrophages.
Photomicrographs show examples of double-staining immunofluorescence
of CD16/32 and Iba-1 on brain sections of ischemic core and border zones
acquired from three experimental groups at 6 days after stroke. Illustrative
4×, 20× - close-up magnifications visualize the changes in CD16/32
expression by Iba-1 positive cells (a-c). Scale bar: 50 μm. Time course
for the CD16/32 expression by Iba-1+ cells in the ipsilateral and
contralateral ROIs of cortex and striatum in miR-124 treated group
compared to the only MCAO and negative control group at day 6 (d) and
day 14 (e). Quantification results confirm that intracranial injection of miR-
124 at day 2 after MCAO results in a significant decrease of Iba-1+ cells
expressing CD16/32 monitored at day 6 post stroke (d). Representative
graph shows no differences at CD16/32 expression by Iba-1+ cells at day
14 after stroke between groups (e). n = 5–6 mice in each group and for each
time point. *P<0.05, **P<0.01 at one-way ANOVA (with Bonferroni’s
post hoc test). Scale bar 50 μm
J Neuroimmune Pharmacol (2016) 11:733–748 743
744 J Neuroimmune Pharmacol (2016) 11:733–748
enhanced and M1 in parallel decreased, late phase application
only decreased the pro-inflammatory M1 phenotype but left
the M2 marker expression unaffected. This is in full agree-
ment with our own earlier observation, where we showed that
Arg-1, an M2 marker like CD206 used in the present study,
was upregulated upon early miR-124 administration, but that
this upregulation was lost whenmiR-124 was applied after ten
days (Hamzei Taj et al. 2016). The miR-124 administration at
this late stage when the pro-inflammatory phase has become
dominant (Hu et al. 2012) could not improve the neurological
deficit. Modulating the neuroinflammation in neurodegenera-
tive disorders as a therapeutic strategy is only now emerging,
and to our knowledge this is the first study to analyze the
effect of polarization modulation of microglia/macrophage
cells by liposomated miR-124 at different time points after
stroke.
The M1 polarization process gradually increases from day
3 onward after stroke onset (Hu et al. 2012). We therefore
addressed the question whether the delayed administration
of miR-124 still has an effect on modifying the M1/M2 polar-
ization. The strength of neuroinflammation modulation (i.e.
M1:M2 ratio) in response to late miR-124 administration
was lower compared to application at the early stage, which
caused a pronounced increase in microglia/macrophages pop-
ulation with M2 phenotype and a noticeable decrease in the
population with M1 phenotype. At this late time point, we
observed a considerable decrease in M1 surface marker ex-
pression by Iba-1+ cells particularly in the border and core
regions of the striatal lesion by miR-124 administration.
Furthermore, the higher level of 50th percentile of the M2
surface marker expression of the ipsilateral striatal regions in
the miR-124 treated group shows a small tendency of in-
creased M2 surface marker expression by Iba-1+ cells at this
time point. Consequently, even late miR-124 administration
still has a clear, although somewhat weaker, modulatory effect
on the M1-M2 balance by reducing the M1:M2 ratio, thus
producing a clear, persistent shift towards the anti-inflam-
matory, neuroprotective microglia/macrophage phenotype.
Intrathecal injection of liposomated miR-124 administra-
tion during the first 15 h of carrageenan-induced inflam-
matory hyperalgesia, when the pro-inflammatory process is
prominent in this disease model, could effectively reduce
the M1 surface marker and attenuated the resistant thermal
hyperalgesia, although the efficacy of miR-124 on M1/M2
polarization at later time points of persistent hyperalgesia was
not found (Willemen et al. 2012). Treatment with minocycline,
a selective inhibitor of M1 microglia (Kobayashi et al. 2013),
at day 4 after stroke, improved neurogenesis and functional
recovery (Liu et al. 2007). These results suggest that targeting
the correct phenotype of immune cells at the right time of
neurodegenerative disorders is important for a therapeutic
effect.
Our data demonstrate that miR-124works in the early stage
of stroke by modulating the microglia/macrophage activation
Fig. 7 M1:M2 ratio in the ischemic border zone of the striatum. The ratio
of cell number with M1 (CD16/32) and M2 (CD206) phenotype was
determined for the ischemic border zone of the striatum for all three
animal groups (mir-124 treated; negative control; MCAO-only). a and
b show the data for miR-124 injection at day 2 after stroke and
analysis at day 6 (a) and at day 14 (b). c depicts the situation for
delayed miR-124 injection at day 10 and analysis 4 days later, at day
14. While the M1:M2 ratio of the miR-124 treated group is slowly
increasing with longer period after injection and with later injection
time after stroke, it remains always substantially lower than the
control groups. Results are expressed as mean ± SEM. P < 0.05, as
compared with control groups using Kruskal-Wallis H test for (a) and (b)
and independent one-tailed Student’s t-test for (c)
Fig. 6 Effects of delayed miR-124 injection on M1/M2 phenotype of
microglia/macrophages. Photomicrographs show examples of double-
staining immunofluorescence of CD206 + Iba-1 (a-b) and CD16/32 +
Iba-1 (c-d) on brain sections of ischemic core and border zones acquired
from two experimental groups, where miR-124was injected 10 days after
MCAO and polarization of microglia/macrophages was analyzed 14 days
after MCAO. Characteristic 4× and 20× magnifications display the
changes in M2 and M1 markers expression by Iba-1 positive cells
(a-d). Scale bar: 50 μm. Time course for the M2 (e) and M1 (f)
markers expression by Iba-1+ cells in the ipsilateral and contralateral
ROIs of cortex and striatum in miR-124 treated group comparing to the
only MCAO group at day 14. Quantification results show no significant
difference in the M2 expressing Iba-1+ cells number between the miR-
124 treated and the only stroke groups (e). Representative graph confirms
that intracranial injection of miR-124 at day 10 after MCAO results in
pronounced decrease in M1 marker expression by Iba-1+ monitored at
day 14 post stroke (f). n = 5 mice in each group.*P< 0.05, independent
one-tailed Student’s t-test. Scale bar 50 μm
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towardsM2 phenotype, leading to improved functional recov-
ery. Delayed miR-124 administration after stroke still modi-
fied the microglia and macrophagesM1/M2 polarization ratio,
however with reduced intensity. This indicates that a maximal
effect is achieved for miR-124 administration before the
dominance of the pro-inflammatory process of stroke, i.e.
within the first few days when the anti-inflammatory
phase of the M2 phenotype is dominant. Moreover, thera-
peutic effect of the long term observed polarization shift
by miR-124 was limited to early application. It clearly
emphasizes the necessity of careful adjustment of the po-
larization balance of microglia/macrophages in therapeutic
approaches targeting neuroinflammation. Although much
work is still needed before clinical translation, our findings
provide important steps for the understanding of microRNA
based therapy and the underlying mechanisms to develop
microRNA injection into a new approach for functional im-
provement after ischemic stroke.
Conclusions
In conclusion, our study demonstrates that a single injection of
miR-124 into the mouse brain in the early phase after stroke is
sufficient to shift theM1/M2 balance of immune cells towards
the anti-inflammatory phenotype which correlates with
behavioral improvement. Further studies are needed to
clarify the mechanism and identify the targeted immune
cells. Nevertheless, our findings highlight the important
role of immune cells after stroke and the therapeutic
relevance of their polarization balance. As there is no
treatment for sub-acute stroke available, miR-124 evolves as a
promising novel therapeutic approach.
CCA, common carotid artery; C/EBP-α, CCAATenhancer
binding protein α; CNS, central nervous system; ECA, exter-
nal carotid artery; FIZZ, found in inflammatory zone; Iba-1,
ionized calcium-binding adapter molecule 1; ICA, internal
carotid artery; IFN, interferon; IL, interleukin; iNOS, inducible
Fig. 8 MiR-124 improves functional recovery after stroke. Behavioral
functional test was evaluated by the modified neurological deficit scores
(mNDS) before and after MCAO. Representative graphs of the
experimental groups subjected to miR transplantation at 2 days after
MCAO and perfused at day 6 (a) and day 14, respectively (b) show
that miR-124 treatment at 2 days after MCAO significantly improved
the functional recovery at day 4 and day 6 after stroke. Representative
graphs of the experimental group subjected to miR transplantation at day
10 after MCAO with perfusion at day 14 (c) show no significant
differences among the miR-124 treated group and only MCAO group.
n = 5–6 mice in each group and for each time point. Values are
mean ± SD. *P< 0.05, as compared with control groups using Kruskal-
Wallis H test for (a) and (b), and Wilcoxon-Mann-Whitney test for (c).
Changes of M1 expression within the ischemic hemisphere linearly
correlates with neurological deficit score changes in the ischemic mice
(Spearman r2 = 0.530, p = 0.017) (d). Changes of M2 expression within
the ischemic hemisphere inversely correlates to neurological deficit score
changes in the ischemic mice (Spearman r2 = 0.425, p = 0.041) (e)
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NO synthetase; IQR, interquartile range; KPBS, potassium
phosphate buffered saline; MCAO, middle cerebral artery
occlusion; MHC, major histocompatibility complex; MMR,
mouse anti-mannose receptor; mNDS, modified neurologi-
cal deficit score; mRNA, messenger ribonucleic acid; MRI,
magnetic resonance imaging; MSME, multi slice multi echo;
PBS, phosphate buffered saline; PFA, paraformaldehyde; RF,
radio frequency; RNA, ribonucleic acid; siRNA, small inter-
fering ribonucleic acid; TGF-β, tumor growth factor β;
TNF-α, tumor necrosis factor α.
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